Cargando…
Severe Multi-Resistant Pemphigus vulgaris: prolonged remission with a single cycle of Rituximab
Pemphigus vulgaris is an autoimmune bullous disease whose therapy is based on systemic corticosteroids, with or without immunosuppressants. Rituximab is a chimeric monoclonal antibody of the IgG class, directed at a specific CD20 B cell surface antigen, used in pemphigus vulgaris empirically since 2...
Autores principales: | Corral, Isabela Soubhia, de Freitas, Thais Helena Proença, de Aquino, Renata Telles Rudge, Koller, Daniella Abbruzzini S., Magliari, Maria Elisa Ruffolo, Muller, Helena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Dermatologia
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3760947/ https://www.ncbi.nlm.nih.gov/pubmed/24068143 http://dx.doi.org/10.1590/abd1806-4841.20131990 |
Ejemplares similares
-
Rituximab in the Treatment of Pemphigus Vulgaris
por: Zakka, Labib R., et al.
Publicado: (2012) -
Rituximab therapy improves recalcitrant Pemphigus vulgaris
por: Noormohammadpour, Pedram, et al.
Publicado: (2015) -
Cerebral toxoplasmosis after rituximab for pemphigus vulgaris
por: Lee, Erica B., et al.
Publicado: (2019) -
AZD-1222/rituximab: Pemphigus vulgaris and pemphigus vulgaris flare-up: 2 case reports
Publicado: (2022) -
Refractory pemphigus vulgaris treated with rituximab and mycophenolate
mofetil
por: Biot, Stephanie Del Rio Navarrete, et al.
Publicado: (2014)